Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zytiga
Biotech
Astellas pays $175M for Propella to snag rival to J&J's Zytiga
Astellas is buying Propella Therapeutics and its clinical-phase challenger to Johnson & Johnson’s fast-fading prostate cancer blockbuster Zytiga.
Nick Paul Taylor
Nov 16, 2023 7:18am
Janssen can't conjure up patients for ESSA prostate cancer trial
Oct 31, 2022 10:20am
Arvinas eyes a busy 2021 as protein degraders gather steam
Dec 14, 2020 10:32am
Researchers create test to predict response to Xtandi, Zytiga
May 5, 2017 9:24am
Advantagene closes a $14.2M I/O raise through NCS
Sep 12, 2016 9:12am